ClinicalTrials.gg
TerminatedNCT04413253Updated Oct 27, 2026Results posted

Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease

A Phase 4 interventional study of Lifitegrast 5% Ophthalmic Solution and Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution in Dry Eye Syndromes, sponsored by Eye Surgeons of Indiana. Terminated at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Eye Surgeons of Indiana · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
Unable to recruit
Updated Oct 27, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies testing dexamethasone in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. Dexamethasone · Dry Eye Syndromes.

Enrollment
16th of 16
5 · median 36
Started
2020
with 4 others
Phase 4
12 of 16
none open now
Registered
9th of 16
by date
Lead sponsor
2 of 16
Eye Surgeons of Indiana

Among the 16 studies testing dexamethasone in Dry Eye Syndromes, this one is the 16th largest by enrollment, is one of 5 that started in 2020, is one of 12 in phase 4, and was the 9th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

None of the 16 studies testing dexamethasone in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →

Where they have run

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing dexamethasone in Dry Eye Syndromes as a file.
02

Study summary

To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in patients with dry eye who are beginning treatment with Xiidra (lifitegrast ophthalmic solution) to reduce the signs and symptoms of dry eye disease.

Read the detailed description

This prospective study will use a fellow-eye design for 20 participants, 40 eyes. All eyes will receive bilateral Xiidra. The most symptomatic eye will be selected to receive DEXTENZA® insertion on the day Xiidra is prescribed (study eye), while the other eye will be assigned to receive sham punctum dilation (control eye). If there is no obvious symptomatic difference, the right eye will receive the intracanalicular insert. The study group will consist of 20 eyes receiving DEXTENZA® insertion. The control group will consist of 20 eyes receiving sham punctum dilation. Thus, for every eye in the study group, there will be a paired eye with similar baseline characteristics in the control group sourced from the same participant. This fellow-eye design allows for greater control of potential confounders tied to participants' systemic and ocular health.

03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A patient's study eye must meet the following criteria to be eligible for inclusion in the study:

  • 18 years of age or older
  • Signs and symptoms of DED
  • Consent to treat with topical immunomodulator
  • Willing and able to comply with clinic visits and study related procedures
  • Willing and able to sign the form

Exclusion criteria

Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from the study:

  • Patients under the age of 18.
  • Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)
  • Active infectious systemic disease
  • Active infectious ocular or extraocular disease
  • Altered nasolacrimal flow of either acquired, induced, or congenital origin
  • to dexamethasone
  • Patients who have been on topical immunomodulating agents in the previous 3 months to their baseline visit
  • Patient being treated with either topical, oral, or intravenous agents, immunomodulating agents, or (including NSAIDS)
  • Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
5 participants (actual)

Study arms

  • Active comparator
    Xiidra Only Group

    Patients with dry eye disease Xiidra only

    Drug: Lifitegrast 5% Ophthalmic Solution

  • Experimental
    Xiidra + Dextenza Group

    Patients with dry eye disease Xiidra + Dextenza

    Drug: Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution

Interventions

  • DrugLifitegrastStudies of LifitegrastLifitegrast pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    To reduce signs and symptoms of dry eye disease

    Also known as: Xiidra

  • DrugDexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution

    Drug page: DexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    To determine the outcomes of reduction of signs and symptoms of dry eye disease with DEXTENZA as an added therapy, in addition to Xiidra therapy.

    Also known as: Dextenza, Xiidra

06

What researchers measure

Primary outcomes

  1. Mean Change in Ocular Surface Staining

    As measured by sodium fluorescein and lissamine green

    Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

  2. Patient Preference for Therapy

    As measured by COMTOL Survey

    Time frame: Assessed at Week 12 Visit

Secondary outcomes

  1. Mean Change in MMP-9

    As measure by InflammaDry

    Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

  2. Mean Change in Conjunctival Injection

    As measured on a scale of 0-4 and graded by the physician

    Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

  3. Change From Baseline in Meibomian Gland Scores (Expressibility and Quality)

    As measured on a grading scale 1 to 4 and graded by the physician

    Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

  4. Mean Change in Tear Break-up Time (TBUT)

    As measured by TBUT testing

    Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

  5. Mean Change in Tear Osmolarity

    As measured by Tear Lab

    Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

  6. Mean Change in DEQ-5

    As measured by the DEQ-5 Questionnaire

    Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

  7. Mean Change in Best-corrected Visual Acuity (BCVA)

    As measure by ETDRS

    Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

07

Results

Posted Oct 27, 2026

Participant flow

The study was terminated due to inability to recruit. Five participants provided informed consent and were enrolled; however, no participants were assigned to an Arm/Group or received study intervention.

Participant flow — Overall Study
MilestoneXiidra Only GroupXiidra + Dextenza Group
Started00
Completed00
Not completed00

Outcome measures

PrimaryMean Change in Ocular Surface Staining

As measured by sodium fluorescein and lissamine green

Time frame:
Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

No measurements were reported for this outcome.

PrimaryPatient Preference for Therapy

As measured by COMTOL Survey

Time frame:
Assessed at Week 12 Visit

No measurements were reported for this outcome.

SecondaryMean Change in MMP-9

As measure by InflammaDry

Time frame:
Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

No measurements were reported for this outcome.

SecondaryMean Change in Conjunctival Injection

As measured on a scale of 0-4 and graded by the physician

Time frame:
Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

No measurements were reported for this outcome.

SecondaryChange From Baseline in Meibomian Gland Scores (Expressibility and Quality)

As measured on a grading scale 1 to 4 and graded by the physician

Time frame:
Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

No measurements were reported for this outcome.

SecondaryMean Change in Tear Break-up Time (TBUT)

As measured by TBUT testing

Time frame:
Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

No measurements were reported for this outcome.

SecondaryMean Change in Tear Osmolarity

As measured by Tear Lab

Time frame:
Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

No measurements were reported for this outcome.

SecondaryMean Change in DEQ-5

As measured by the DEQ-5 Questionnaire

Time frame:
Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

No measurements were reported for this outcome.

SecondaryMean Change in Best-corrected Visual Acuity (BCVA)

As measure by ETDRS

Time frame:
Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit

No measurements were reported for this outcome.

Adverse events

Collected over Not applicable. No participants started the trial or received study intervention prior to study termination on April 11, 2022; therefore, adverse events were not monitored or assessed.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Xiidra + Dextenza Group———
Xiidra Only Group———

Baseline characteristics

No baseline characteristics were collected because no participants started the trial, were assigned to an Arm/Group, or received study intervention prior to study termination. Therefore, the overall number of baseline participants is 0.

Age, Categorical
Age, CategoricalXiidra Only GroupXiidra + Dextenza GroupTotal
<=18 years———
Between 18 and 65 years———
>=65 years———
Age, Continuous
Age, ContinuousXiidra Only GroupXiidra + Dextenza GroupTotal
Sex: Female, Male
Sex: Female, MaleXiidra Only GroupXiidra + Dextenza GroupTotal
Female———
Male———
Race (NIH/OMB)
Race (NIH/OMB)Xiidra Only GroupXiidra + Dextenza GroupTotal
American Indian or Alaska Native———
Asian———
Native Hawaiian or Other Pacific Islander———
Black or African American———
White———
More than one race———
Unknown or Not Reported———
Region of Enrollment
Region of Enrollment(participants)Xiidra Only GroupXiidra + Dextenza GroupTotal
08

Study locations

1 site
  • Eye Surgeons of Indiana
    Indianapolis, Indiana 46040, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Apr 2022, 20 months.

Results were first posted in Oct 2026, 4 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2020
First posted
Jun 2, 2020
StartActual
Aug 1, 2020
Primary completionActual
Apr 11, 2022
CompletionActual
Apr 11, 2022
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedMean changeChange in ocular surface stainingOcular Surface StainingTime frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
  • EditedPatient Preference for therapyTherapyTime frame: Assessed at Week 12 Visit
Oct 27, 2026
Documents
Oct 27, 2026
Secondary outcomes
7 edited
What changed in the outcomes
  • EditedMean changeChange in MMP-9Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
  • EditedMean changeChange in tear breakTear Break-up timeTime (TBUT)Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
  • EditedMean changeChange in conjunctival injectionConjunctival InjectionTime frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
  • EditedChange from baselineFrom Baseline in meibomian gland scoresMeibomian Gland Scores (expressibilityExpressibility and qualityQuality)Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
  • EditedMean changeChange in tear osmolarityTear OsmolarityTime frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
  • EditedMean changeChange in DEQ-5Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
  • EditedMean changeChange in Best-corrected Visual Acuity (BCVA)Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Results posted
    Documents Study protocol ↗ posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedMean changeChange in ocular surface stainingOcular Surface StainingTime frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
    • EditedPatient Preference for therapyTherapyTime frame: Assessed at Week 12 Visit
    Secondary outcomes 7 edited
    What changed in the outcomes
    • EditedMean changeChange in MMP-9Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
    • EditedMean changeChange in tear breakTear Break-up timeTime (TBUT)Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
    • EditedMean changeChange in conjunctival injectionConjunctival InjectionTime frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
    • EditedChange from baselineFrom Baseline in meibomian gland scoresMeibomian Gland Scores (expressibilityExpressibility and qualityQuality)Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
    • EditedMean changeChange in tear osmolarityTear OsmolarityTime frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
    • EditedMean changeChange in DEQ-5Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
    • EditedMean changeChange in Best-corrected Visual Acuity (BCVA)Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04413253
Lead sponsor
Eye Surgeons of Indiana
Responsible party
Sponsor
First posted
Jun 2, 2020
Start date
Aug 1, 2020
Primary completion
Apr 11, 2022
Completion
Apr 11, 2022
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

Damon Dierker, OD, FAAO
principal investigator · Eye Surgeons of Indiana

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion